Summit Therapeutics revenue and financials
$17.31Change from previous close: +0.23%Absolute change: +$0.04
Fiscal year ending in December. Sources and method on the page Methodology and sources.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | FY to Jan 2019 | FY to Jan 2018 | FY to Jan 2017 | FY to Jan 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -323 | -142 | -76.8 | -41.6 | -72.6 | -48.1 | -35.1 | -14.5 | 12.1 | -17.2 |
| Depreciation and amortization | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | — | — | — |
| Capital expenditure | -0.7 | -0.1 | -0.1 | -0.6 | -0.3 | -0.4 | -0.2 | -0.4 | -0.1 | -0.1 |
| Investing cash flow | -174 | -205 | -588 | -0.6 | -0.3 | — | — | — | — | — |
| Financing cash flow | 618 | 381 | 86.5 | 620 | 77.9 | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | 0.0 | 0.0 | — | — | — |
| Debt issued | — | 0.0 | 0.0 | 545 | 110 | — | — | — | — | — |
| Debt repaid | 0.0 | -100 | -24.7 | -25.0 | -110 | — | — | — | — | — |
| Effect of exchange rates | 0.1 | -0.0 | 0.8 | -1.2 | 0.4 | — | — | — | — | — |
| Net change in cash | 120 | 33.8 | -577 | 577 | 5.4 | — | — | — | — | — |
| Free cash flow | -324 | -142 | -76.9 | -42.2 | -72.9 | — | — | — | — | — |
| Levered free cash flow | 84.1 | -88.9 | -222 | -320 | -38.3 | — | — | — | — | — |